Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.60 |
| ▸ | ESR1 | P03372 | 13/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095297 | 1.00 | ESR2 (0.60) | ESR2ESR1ABHD6GRIN1GRIN2B | |
| SCHEMBL15290710 | 0.87 | ESR1 (0.44) | ESR2ESR1ABHD6DRD1 | |
| SCHEMBL1095538 | 0.84 | ESR1 (0.65) | ESR2ESR1ABHD6DRD1 | |
| SCHEMBL1095168 | 0.84 | ESR1 (0.52) | ESR2ESR1ABHD6 | |
| SCHEMBL4937667 | 0.84 | ESR1 (0.65) | ESR2ESR1ABHD6DRD1 | |
| SCHEMBL16582898 | 0.84 | ESR2 (0.43) | ESR2ESR1GRIN1GRIN2BDRD1 | |
| SCHEMBL23745324 | 0.83 | ESR1 (0.45) | ESR2ESR1ABHD6DRD1DRD2 | |
| SCHEMBL31121185 | 0.83 | ESR1 (0.45) | ESR2ESR1ABHD6DRD1DRD2 | |
| SCHEMBL14282038 | 0.83 | ABHD6 (0.55) | ESR2ESR1ABHD6DRD1 | |
| SCHEMBL1095022 | 0.82 | ESR1 (0.45) | ESR2ESR1DRD1DRD2DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | ESR2 456/4885ESR1 1181/4885ABHD6 1206/4885 |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | ESR2 448/4885ESR1 1192/4885ABHD6 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.